Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review

Alexander V van Schoonhoven*, Judith J Gout-Zwart, Marijke J S de Vries, Antoinette D I van Asselt, Evgeni Dvortsin, Pepijn Vemer, Job F M van Boven, Maarten J Postma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
163 Downloads (Pure)


BACKGROUND: Type 2 diabetes mellitus (T2DM) is an established risk factor for cardiovascular and nephropathic events. In the Netherlands, prevalence of T2DM is expected to be as high as 8% by 2025. This will result in significant clinical and economic impact, highlighting the need for well-informed reimbursement decisions for new treatments. However, availability and consistent use of costing methodologies is limited.

OBJECTIVE: We aimed to systematically review recent costing data for T2DM-related cardiovascular and nephropathic events in the Netherlands.

METHODS: A systematic literature review in PubMed and Embase was conducted to identify available Dutch cost data for T2DM-related events, published in the last decade. Information extracted included costs, source, study population, and costing perspective. Finally, papers were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).

RESULTS: Out of initially 570 papers, 36 agreed with the inclusion criteria. From these studies, 150 cost estimates for T2DM-related clinical events were identified. In total, 29 cost estimates were reported for myocardial infarction (range: €196-€27,038), 61 for stroke (€495-€54,678), fifteen for heart failure (€325-€16,561), 24 for renal failure (€2,438-€91,503), and seventeen for revascularisation (€3,000-€37,071). Only four estimates for transient ischaemic attack were available, ranging from €587 to €2,470. Adherence to CHEERS was generally high.

CONCLUSIONS: The most expensive clinical events were related to renal failure, while TIA was the least expensive event. Generally, there was substantial variation in reported cost estimates for T2DM-related events. Costing of clinical events should be improved and preferably standardised, as accurate and consistent results in economic models are desired.

Original languageEnglish
Article numbere0221856
Number of pages22
JournalPLoS ONE
Issue number9
Publication statusPublished - 6-Sep-2019

Cite this